Kronos Bio, Inc. (KRON)
NASDAQ$0.94
Market Cap
$56.72M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
80 of 924
Rank in Industry
58 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
KRON Insider Trading Activity
KRON Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $3,852,882 | 5 | 100 |
Sells | $0 | 0 | 0 |
Related Transactions
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 5 | $3.85M | 0 | $0 | $3.85M |
About Kronos Bio, Inc.
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase inhibitor for acute myeloid leukemia patients. The company planned registrational phase 3 clinical trial of ENTO in combination with induction chemotherapy …
Insider Activity of Kronos Bio, Inc.
Over the last 12 months, insiders at Kronos Bio, Inc. have bought $3.85M and sold $0 worth of Kronos Bio, Inc. stock.
On average, over the past 5 years, insiders at Kronos Bio, Inc. have bought $10.34M and sold $2.57M worth of stock each year.
Highest buying activity among insiders over the last 12 months: BISCHOFBERGER NORBERT W (PRESIDENT & CEO) — $3.85M.
The last purchase of 204,670 shares for transaction amount of $254,957 was made by BISCHOFBERGER NORBERT W (PRESIDENT & CEO) on 2024‑06‑28.
List of Insider Buy and Sell Transactions, Kronos Bio, Inc.
| 2024-06-28 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 204,670 0.4456% | $1.25 | $254,957 | -20.97% | ||
| 2024-06-27 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 410,848 0.8369% | $1.17 | $478,843 | -18.33% | ||
| 2024-06-12 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 881,913 1.586% | $1.24 | $1.1M | -23.27% | ||
| 2024-06-11 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 744,308 1.1787% | $1.09 | $814,571 | -14.50% | ||
| 2024-06-10 | BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 1.38M 2.1146% | $0.88 | $1.21M | +3.46% | ||
| 2024-02-21 | Sale | Lin Charles Y | SR VP, RESEARCH & DEVELOPMENT | 12,036 0.0205% | $1.05 | $12,685 | -4.76% | |
| 2024-02-21 | Sale | Frisbee Allison | SR VP, CORP OPERATIONS & LEGAL | 12,105 0.0206% | $1.05 | $12,757 | -4.76% | |
| 2024-02-21 | Sale | Olek Elizabeth A | SR VP, CLINICAL SCIENCE | 7,368 0.0126% | $1.05 | $7,765 | -4.76% | |
| 2024-01-04 | Sale | Kosacz Barbara | COO & General Counsel | 10,676 0.0179% | $1.18 | $12,636 | -15.70% | |
| 2024-01-04 | Sale | DiMartino Jorge | Chief Medical Officer & VP | 12,009 0.0201% | $1.18 | $14,214 | -15.70% | |
| 2024-01-04 | Sale | Dinsmore Christopher | Chief Scientific Officer | 7,366 0.0124% | $1.18 | $8,718 | -15.70% | |
| 2023-12-12 | Sale | DiMartino Jorge | Chief Medical Officer & VP | 17,367 0.0299% | $1.30 | $22,664 | -20.38% | |
| 2023-12-12 | Sale | Dinsmore Christopher | Chief Scientific Officer | 10,032 0.0173% | $1.30 | $13,092 | -20.38% | |
| 2023-11-17 | BISCHOFBERGER NORBERT W | President & CEO | 97,935 0.167% | $1.08 | $106,162 | -4.96% | ||
| 2023-11-16 | BISCHOFBERGER NORBERT W | President & CEO | 262,433 0.4271% | $1.00 | $261,514 | 0.00% | ||
| 2023-11-15 | BISCHOFBERGER NORBERT W | President & CEO | 1.37M 2.1008% | $0.80 | $1.1M | +16.48% | ||
| 2023-07-06 | Sale | Al-Wakeel Yasir B. | Chief Financial Officer | 9,617 0.0159% | $1.75 | $16,852 | -36.56% | |
| 2023-07-06 | Sale | DiMartino Jorge | Chief Medical Officer & VP | 10,818 0.0178% | $1.75 | $18,956 | -36.56% | |
| 2023-07-06 | Sale | Dinsmore Christopher | Chief Scientific Officer | 6,634 0.0109% | $1.75 | $11,625 | -36.56% | |
| 2023-02-24 | Sale | Al-Wakeel Yasir B. | Chief Financial Officer | 9,026 0.0167% | $1.74 | $15,665 | -19.76% |
Total: 52
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| BISCHOFBERGER NORBERT W | PRESIDENT & CEO | 10802138 17.9019% | $10.15M | 11 | 0 | <0.0001% |
| Bischofberger Norbert W. & Inger A. Revocable Inter Vivos Trust | 10 percent owner | 4370496 7.243% | $4.11M | 1 | 0 | <0.0001% |
| Stampacchia Otello | 3818283 6.3279% | $3.59M | 1 | 0 | <0.0001% | |
| Omega Fund V, L.P. | 10 percent owner | 3818283 6.3279% | $3.59M | 1 | 0 | <0.0001% |
| MARTIN JOHN C | director | 1952364 3.2356% | $1.84M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$6,787,959 | 35 | 49.84% | $60.62M | |
$459,011,221 | 33 | 33.04% | $57.94M | |
$144,247,213 | 29 | 10.15% | $64.24M | |
$2,239,226 | 28 | 3.41% | $63.36M | |
$26,736,140 | 20 | -18.64% | $54.85M |
KRON Institutional Investors: Active Positions
| Increased Positions | 23 | +40.35% | 3M | +14.2% |
| Decreased Positions | 17 | -29.82% | 3M | -14.37% |
| New Positions | 11 | New | 2M | New |
| Sold Out Positions | 7 | Sold Out | 1M | Sold Out |
| Total Postitions | 63 | +10.53% | 18M | -0.16% |
KRON Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Vida Ventures Advisors, Llc | $2,765.00 | 4.61% | 2.77M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $1,923.00 | 3.21% | 1.92M | 0 | 0% | 2024-12-31 |
| Millennium Management Llc | $1,717.00 | 2.86% | 1.72M | -329,302 | -16.1% | 2024-12-31 |
| Acadian Asset Management Llc | $1,305.00 | 2.17% | 1.3M | 0 | 0% | 2024-12-31 |
| Wildcat Capital Management, Llc | $1,298.00 | 2.16% | 1.3M | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $1,172.00 | 1.95% | 1.17M | +192,754 | +19.69% | 2024-12-31 |
| Tang Capital Management Llc | $1,003.00 | 1.67% | 1M | +1M | New | 2024-12-31 |
| Siren, L.L.C. | $843.00 | 1.41% | 842,954 | 0 | 0% | 2024-12-31 |
| Blackrock, Inc. | $774.00 | 1.29% | 774,276 | -28,032 | -3.49% | 2024-12-31 |
| Peapod Lane Capital Llc | $563.00 | 0.94% | 562,620 | +562,620 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.